February 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial

Bert van Meurs/LinkedIn

Nov 3, 2025, 08:15

Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial

Bert van Meurs, Chief Business Leader Image Guided Therapy and Member of the Executive Committee at Royal Philips, shared on LinkedIn:

”New late-breaking results from the iMODERN trial, presented at TCT 2025, bring important clarity for heart attack patients with multi-vessel disease.

This global study confirms that treating additional lesions during the initial procedure is just as safe as waiting to stage treatment, giving clinicians more flexibility to tailor care to each patient’s needs.

Complementary findings from the ILIAS ANOCA study also highlight the value of physiology-guided assessment and personalized therapy for patients with angina but no obstructive coronary arteries, resulting in sustained improvements in quality of life.

I’m proud that Philips solutions supported both of these impactful studies.

Together with our clinical partners, we’re helping advance evidence-based, individualized cardiovascular care for patients worldwide.”

Read the full announcement here.

Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial